Cocrystal Pharma (NASDAQ:COCP – Get Free Report) released its earnings results on Thursday, August 13th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06), FiscalAI reports. The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.10 million.
Cocrystal Pharma Stock Performance
NASDAQ COCP opened at $1.18 on Wednesday. The business’s fifty day moving average is $1.04 and its 200 day moving average is $1.12. Cocrystal Pharma has a fifty-two week low of $0.76 and a fifty-two week high of $2.67. The company has a market capitalization of $22.73 million, a PE ratio of -1.55 and a beta of 1.48.
Wall Street Analyst Weigh In
Separately, Weiss Ratings lowered Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Cocrystal Pharma currently has an average rating of “Sell”.
Hedge Funds Weigh In On Cocrystal Pharma
A hedge fund recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC acquired a new stake in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned approximately 0.24% of Cocrystal Pharma at the end of the most recent reporting period. Institutional investors and hedge funds own 6.72% of the company’s stock.
About Cocrystal Pharma
Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.
The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.
See Also
- Five stocks we like better than Cocrystal Pharma
- Lululemon’s Problems May Not Be a Warning for Every Athleticwear Stock
- Roper Technologies In Rebound and a Hot Buy Despite Insider Selling
- PayPal’s Takeover Story Ended, But Its Turnaround Story Didn’t
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
